AbbVie (ABBV) EVP receives new stock option and performance share awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AbbVie Inc. executive Jeffrey Ryan Stewart, EVP and Chief Commercial Officer, reported awards of stock options and performance-based shares on February 18, 2026. He acquired an option to buy 26,812 shares that vests in three annual installments starting in February 2027, plus multiple performance-vesting stock and restricted stock unit awards tied to earnings per share, relative total shareholder return, and relative return on equity, with shares scheduled to be issued on February 28, 2026. An additional 1,338 shares are held indirectly by his spouse in a trust, for which he disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Stewart Jeffrey Ryan
Role
EVP, CHIEF COMMERCIAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to Buy) | 26,812 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 26,063 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 9,266 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 9,432 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 8,988 | $0.00 | -- |
| holding | Common Stock, $0.01 par value | -- | -- | -- |
Holdings After Transaction:
Option (Right to Buy) — 26,812 shares (Direct);
Common Stock, $0.01 par value — 79,297 shares (Direct);
Common Stock, $0.01 par value — 1,338 shares (Indirect, By spouse in trust)
Footnotes (1)
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. The reporting person disclaims beneficial ownership of all securities held by his spouse. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,938 on February 18, 2027, 8,937 on February 18, 2028, and 8,937 on February 18, 2029.
FAQ
What did AbbVie (ABBV) executive Jeffrey Ryan Stewart report on this Form 4?
Jeffrey Ryan Stewart reported receiving stock options and performance-based stock awards from AbbVie. The filing details grants of options and performance-vesting share awards that were earned after achievement of specified financial and shareholder return metrics and certified by AbbVie’s Compensation Committee.
What stock option grant did AbbVie (ABBV) give Jeffrey Ryan Stewart?
AbbVie granted Stewart an employee stock option for 26,812 shares under its 2013 Incentive Stock Program. The option is exempt under Rule 16b-3 and becomes exercisable in three annual tranches in 2027, 2028, and 2029, according to the detailed vesting schedule disclosed.
Which performance conditions apply to the AbbVie (ABBV) stock awards in this filing?
The stock awards are subject to performance-vesting based on earnings per share, relative total shareholder return, and a relative return on equity measure. Vesting was released after AbbVie’s Compensation Committee certified goal attainment, with underlying shares scheduled for issuance on February 28, 2026.
How and when do Jeffrey Ryan Stewart’s AbbVie (ABBV) stock options vest?
The employee stock option vests in three annual installments under AbbVie’s 2013 Incentive Stock Program. It becomes exercisable for 8,938 shares on February 18, 2027, and for 8,937 shares on each of February 18, 2028, and February 18, 2029, as disclosed.